JOLLY HEALTHCARE

JOLLY HEALTHCARE JOLLY HEALTHCARE - One Stop Shop for Hard to Find Drugs !! Global Manufacturer & Exporter of Orphan Drugs , Specialty Pharmaceutical & Rapid Diagnostics

Jolly Healthcare is a WHO-GMP certified & UKMHRA compliant pharmaceutical company established in 2009. Now moving to upgrade our facility to USFDA & PICs stature. The company manufactures and sells generic ,branded & OTC pharmaceutical products. Jolly Healthcare has most of its manufacturing facilities located in Excise Free zone @ INDIA. The company produces a wide range of Human Grade Pharmaceuticals in dosage forms including Capsules, Tablets, Ointments, and Liquid Orals.

Up to 1 in 3 patients on some antifungals can develop kidney injury.In serious fungal infections, treatment choice is no...
04/06/2026

Up to 1 in 3 patients on some antifungals can develop kidney injury.

In serious fungal infections, treatment choice is not only about coverage – it is
also about protecting the kidneys that still have to carry the patient through
recovery.

Choosing an antifungal with a lower kidney‑damage risk helps treat the infection
without adding another clinical burden.

[antifungal therapy, kidney injury, nephrotoxicity, invasive fungal infection, ICU
care, treatment safety]


One clear result changes the whole treatment path.An early resistance report helps teams stop overlapping “just-in-case”...
04/06/2026

One clear result changes the whole treatment path.

An early resistance report helps teams stop overlapping “just-in-case” antibiotics
and move faster toward the drug that actually fits the bug in front of them.

The clearer the answer, the sooner therapy becomes targeted, safer and more
rational.

[rapid diagnostics, resistance report, targeted therapy, antibiotic stewardship,
ICU, AMR]


One well‑timed antibiotic dose can be enough.When the first, right antibiotic is working, the goal is to review and step...
04/06/2026

One well‑timed antibiotic dose can be enough.

When the first, right antibiotic is working, the goal is to review and step down – not
keep adding “just in case” days that the patient does not need.

Every unnecessary extra day adds avoidable side‑effects, costs and antimicrobial
resistance for the same infection episode.

[antibiotic duration, de‑escalation, stewardship, ICU, AMR, treatment review]


29/05/2026

ICU clocks keep moving. Fevers keep coming back.

When resistance isn’t checked early, patients stay on broad ‘just‑in‑case’ cover for longer, and hospitals pay in side‑effects, resistance and cost.

Rapid resistance answers can help teams move sooner from guessing to treating what’s really there.

[ICU fever, persistent fever, sepsis, broad‑spectrum antibiotics, antibiotic resistance, rapid resistance testing, stewardship, ICU workflow, lab‑to‑bedside, AMR]

Fever that refuses to settle on “strong” antibiotics should ring a different kind of alarm.In high‑risk ICU patients, a ...
28/05/2026

Fever that refuses to settle on “strong” antibiotics should ring a different kind of alarm.

In high‑risk ICU patients, a persistently septic picture can signal an invasive fungal infection hiding behind the antibiotics, and recognising that early means switching to a different diagnostic and treatment pathway instead of just adding more antibacterials.

[fever on antibiotics, persistent fever, ICU sepsis, think beyond bacteria, invasive fungal infection, high‑risk ICU, antibiotic failure]

When even the “strongest” antibiotic isn’t turning the corner, the problem may not be the drug—it may be the bug.Rapid r...
28/05/2026

When even the “strongest” antibiotic isn’t turning the corner, the problem may not be the drug—it may be the bug.

Rapid resistance tests can flag carbapenemase‑producing organisms within minutes rather than 2–3 days, helping ICU teams move from broad, blind cover to better‑targeted therapy sooner and cut down avoidable broad‑spectrum days.

[sepsis, carbapenemase, rapid diagnostics, CARBA‑5, AMR, ICU, de‑escalation]

Prophylaxis is often the quietest part of a surgery, but it can make all the difference to the patient on the table.For ...
22/05/2026

Prophylaxis is often the quietest part of a surgery, but it can make all the difference to the patient on the table.

For many clean and clean‑contaminated operations, current guidance still favours a single well‑chosen antibiotic, given at the right time and stopped within 24 hours, rather than adding multiple broader agents.

Keeping this “one trusted antibiotic is all it takes” principle alive makes everyday theatre practice simpler for teams and safer for antibiotics.

[surgical prophylaxis, clean surgeries, evidence‑based antibiotic use, AMR stewardship]

21/05/2026

When the patient is crashing, we can’t afford to guess wrong—but we also can’t afford to keep “covering everything” for days.

Rapid carbapenemase results combined with planned de‑escalation let teams step down from broad‑spectrum cover to narrower, guideline‑supported options as soon as it’s safe, cutting unnecessary antibiotic days without sacrificing outcomes.

[sepsis, rapid diagnostics, carbapenemase testing, antibiotic de‑escalation, stewardship, ICU]

When kidneys are already under stress, even the “right” antifungal can become the wrong choice if renal risk is ignored....
19/05/2026

When kidneys are already under stress, even the “right” antifungal can become the wrong choice if renal risk is ignored.

In patients with renal compromise or expected long invasive fungal infection courses, multiple studies show that liposomal amphotericin B can provide effective antifungal cover with a lower risk of kidney injury than conventional amphotericin B deoxycholate, and expert reviews and guidelines
therefore favour liposomal formulations in these high‑risk profiles.

Study references :
- Liposomal amphotericin B and renal safety: review of the evidence and clinical considerations, 2026.
- Nephrotoxicity of three formulations of amphotericin B: trial‑sequential analysis, Arch Med Sci 2020.
- Nephrotoxicity risk assessment of liposomal amphotericin B in clinical practice, 2026.

[invasive fungal infection, renal compromise, liposomal amphotericin B, nephrotoxicity, ICU care, kidney‑safe choices]

When a high‑risk ICU patient stays febrile despite broad‑spectrum antibiotics and source control, the question is no lon...
16/05/2026

When a high‑risk ICU patient stays febrile despite broad‑spectrum antibiotics and source control, the question is no longer “Which antibiotic next?” but “Could this be invasive fungal infection?”.

Invasive fungal diseases in the ICU carry case‑fatality rates that can approach 40–60% in some settings, making early suspicion and timely antifungal thinking as critical as the first antibiotic
choice.

[Sepsis, Non‑response to antibiotics, Invasive fungal infection]

Address

Jaipur
302017

Opening Hours

Monday 10am - 6pm
Tuesday 10am - 6pm
Wednesday 10am - 6pm
Thursday 10am - 6pm
Friday 10am - 6pm
Saturday 10am - 6pm

Telephone

+918003633988

Website

Alerts

Be the first to know and let us send you an email when JOLLY HEALTHCARE posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to JOLLY HEALTHCARE:

Shortcuts

Share

Category